Mechanism of Action
Dual-Helix Membrane Disruption
Esculentin-1a contains two distinct helical regions. The N-terminal helix penetrates the outer membrane of Gram-negative bacteria, while the C-terminal helix disrupts the inner membrane. This two-stage disruption is particularly effective against P. aeruginosa, which has highly resistant outer membrane lipopolysaccharide. The dual-helix mechanism also enables biofilm penetration and killing of biofilm-embedded bacteria.
GLP-1-Like Fragments
A truncated fragment of esculentin-2CHa, [Leu14]-esculentin-2CHa(1-30), was found to activate GLP-1 receptors and stimulate glucose-dependent insulin secretion. This discovery highlights how frog skin AMP scaffolds can be repurposed as metabolic therapeutic leads. The GLP-1R agonist fragments show no antimicrobial activity, indicating complete structural separation of these two pharmacological activities.
Research Summary
CF Pseudomonas Aeruginosa
PreclinicalEsculentin-1a(1-21)NH2, a truncated amidated fragment, kills planktonic and biofilm-forming P. aeruginosa strains from CF patients at MIC values of 1-4 uM. Activity is maintained against mucoid variants that are notoriously resistant to conventional antibiotics. Lipid nanoparticle formulations of this fragment have been developed to enable pulmonary delivery and are in preclinical development for CF lung infections.
GLP-1 Receptor Activity
PreclinicalEsculentin-2CHa fragments activate GLP-1 receptors with potency comparable to GLP-1 itself in cell-based assays. In type 2 diabetic mouse models, these fragments improve glucose tolerance and stimulate insulin secretion. Their structural distinctness from peptide-based GLP-1RAs like semaglutide offers potential for novel scaffolds with different pharmacokinetic profiles.
Calculate your Esculentin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| CF P. aeruginosa (in vitro) | 1-4 uM (peptide fragment) | Single exposure | Direct application |
| GLP-1R activation (in vitro) | 10-100 nM (fragment) | Continuous exposure | Research only |
No human research protocols. All data preclinical.
Interactions
Safety Profile
Full-length esculentin-1a shows hemolytic activity limiting systemic use. Truncated fragments designed for CF treatment show improved selectivity with reduced mammalian cell toxicity. Lipid nanoparticle formulation further limits systemic absorption. No human clinical data.
References
- [1]Mangoni ML, et al. (2008). Effects of the antimicrobial peptide temporin L on cell morphology, membrane permeability and viability of Escherichia coli. Biochem J, 380(3), 859-865.
- [2]Casciaro B, et al. (2017). Esculentin-1a(1-21)NH2: A frog-skin derived peptide for microbial keratitis. Sci Rep, 7, 46457.